P 52
Latest Information Update: 31 Aug 2007
Price :
$50 *
At a glance
- Originator Phytopharm
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Burns
Most Recent Events
- 12 Feb 1998 Phase-II clinical trials for Burns in United Kingdom (Topical)
- 29 Jan 1998 Phase-I clinical trials for Burns in United Kingdom (Topical)